

Treatment and Management Strategies for Advanced Breast Cancer Patients:

Consultation With the Experts

Friday, 26 September 2014

14.00 – 15.30

Barcelona Auditorium, IFEMA Convention and Congress Centre
Madrid, Spain

14.00–14.05	Welcome and Introductions	Stephen Chia, MD, FRCP – <i>Chair</i>
14.05–14.35	Treatment Options for Endocrine-Resistant Disease	Stephen Chia, MD, FRCP – <i>Chair</i>
14.35–15.05	Managing Treatment-Related Adverse Events Associated With Endocrine-Resistant HR+/HER2- Advanced Breast Cancer	TBD
15.05–15.25	What Is on the Horizon for Treating HR+/HER2- Advanced Breast Cancer?	Angelo Di Leo, MD, PhD
15.25–15.30	Conclusions	Stephen Chia, MD, FRCP – <i>Chair</i>

Biomarkers in Clinical Decision-Making:

Targeted Molecular Therapy in Advanced NSCLC

Friday, 26 September 2014

16.30 – 18.00

Barcelona Auditorium, IFEMA Convention and Congress Centre
Madrid, Spain

16.30–16.35	Welcome and Objectives	Giorgio Scagliotti, MD, PhD – <i>Chair</i>
16.35–17.00	Role of Biomarkers in NSCLC	Giorgio Scagliotti, MD, PhD
17.00–17.25	Actionable Biomarkers in NSCLC: What Should We Be Testing for and How?	Fernando López-Ríos, MD, PhD
17.25–17.50	New Targeted Therapies in ALK-Positive NSCLC	Jürgen Wolf, MD, PhD
17.50–18.00	Summary and Close	Giorgio Scagliotti, MD, PhD – <i>Chair</i>